A top former executive at Madrigal Pharmaceuticals has filed a lawsuit in federal court alleging he was forced to resign after raising internal concerns about the safety of the company’s approved medication for patients with the liver disease known as MASH. Michael Charlton, a physician, was Madrigal’s senior vice president, head of clinical development, from October 2024 until January 2026. His lawsuit, filed on Oct. 9 in the Northern District of Illinois, accuses Madrigal of retaliation under federal whistleblower-protection statutes and seeks reinstatement or monetary damages. “Charlton’s mandate was to safeguard the safety, scientific integrity and accuracy of the clinical trials and disclosures supporting Madrigal’s flagship drug. He did exactly that. Madrigal punished him for it,” the lawsuit alleges. Continue to STAT+ to read the full story…
CryptoAlerta — análise de criptomoedas e mercado em tempo real